statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GH Research PLC (NASDAQ:GHRS  Get Free Report) shares gapped up prior to trading on Thursday . The stock had previously closed at $10.30, but opened at $10.55. GH Research shares last traded...

GH Research (NASDAQ:GHRS) Shares Gap Up to $10.30

In trading on Tuesday, shares of GH Research PLC (GHRS) crossed above their 200 day moving average of 9.15, changing hands as high as 9.39 per share. GH Research PLC shares are currently...

GH Research (GHRS) Shares Cross Above 200 DMA

Over the last three days, A.I.dvisor has detected that GHRS's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

GH Research (GHRS, $8.18) Aroon Indicator entered an Uptrend on March 07, 2024.

GH Research (NASDAQ:GHRS  Free Report) had its price objective reduced by JMP Securities from $50.00 to $39.00 in a research note published on Friday morning, Benzinga reports. They currently...

GH Research (NASDAQ:GHRS) Price Target Cut to $39.00 by Analysts at JMP Securities

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

GH Research price target lowered by $11 at JMP Securities, here's why

GH Research reports FY23 EPS (68c), consensus (67c)

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024Phase 2a clinical trial of GH001 in postpartum...

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

This indicator may be signaling GHRS's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

GH Research (GHRS, $8.55) entered Uptrend as Momentum indicator ascends above 0 level on Feb 27, 2024

GHRS's total volume now sits at 1.1M. The +-0.37% price change was insignificant, leaving IBM's price at $8...

The volume for GH Research stock increased for one day, resulting in a record-breaking daily growth of 854% of the 65-Day Volume Moving Average

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on GH Research (GHRS Research Report). The associated price target i...

Optimistic Outlook for GH Research with Progressing Phase 2 Trials and Strong IP Portfolio Reinforcing Buy Rating

GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

Volume	132,797.00
52-Wk High	$14.64
52-Wk Low	$5.05

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.22	--	--	N/A
Q1'24	-$0.22	-$0.15	31.82%	BEAT
Q4'23	-$0.20	--	--	N/A
Q3'23	-$0.20	-$0.11	45.00%	BEAT
Q2'23	-$0.21	-$0.15	28.57%	BEAT

GHRS GH Research PLC

About

Feed

News

Earnings

Fundamentals